Human medicines
The Estonian human medicinal products market was 154 million euros in wholesale prices in the third quarter of 2026. Compared to the same period of the previous year, the turnover increased 11.7%. The market of human medicines by quarter during last five years is on Figure 1.
Figure 1. Human medicinal products market by quarters, in 2022–2026.
During Q3 2026 there were 24 licensed medicinal product wholesalers, who distributed human medicines to general or hospital pharmacies or to other institutions in Estonia. Sales to general pharmacies covered 72.1%, sales to hospital pharmacies 27.3% and sales to other institutions 0.6% of total medicinal products market. The sales of prescription medicines covered 89% and the sales of over-the-counter medicines 11% of the pharmaceutical market.
The most sold medicines by turnover were antineoplastic and immunomodulating agents (45 million euros), alimentary tract and metabolism medicines (26 million euros) and medicines for nervous system (15 million euros). The market share of these three ATC groups was altogether 55%
The most used medicines by DDD/1000/day were cardiovascular system medicines (542 DDD/1000/day), followed by alimentary tract and metabolism medicines (235 DDD/1000/day) and nervous system medicines (192 DDD/1000/day). These three ATC groups covered 66% of overall medicines consumption in Estonia in Q3 2026. Altogether 1371 different active substances were marketed, and the most used active substances were Rosuvastatin (82 DDD/1000/day), Ramipril (53 DDD/1000/day) and Atorvastatin (51 DDD/1000/day). The total consumption of human medicines was 1466 DDD/1000/day, being 7% higher than in Q3 2025 (Figure 2).
Figure 2. Human medicines total consumption quarterly (DDDs per 1000 inhabitants per day), 2022–2026.
Human medicines Q3 2026 in summary:
- Medicinal products market: 154 million euros
- Sales to pharmacies: 111 million euros
- Sales to hospital pharmacies: 42 million euros
- Sales to other institutions: 1 million euros
- Antineoplastic and immunomodulating agents: 45 million euros
- Alimentary tract and metabolism: 26 million euros
- Medicines for nervous system:15 million euros
Veterinary medicines
The Estonian veterinary medicinal products market was 5.1 million euros in wholesale prices in the third quarter of 2026. Compared to the same period of the previous year the turnover increased by 1.3%. From the overall sales, 93% of veterinary medicines were sold to veterinarians or to the agricultural companies represented by a veterinarian, and 7% to the general and veterinary pharmacies.
Figure 3. Veterinary medicinal products market (medicines used in animals) by quarters, in 2022–2026
The most sold medicines by turnover were antiparasitic products, followed by immunologicals and antiinfectives for systemic use, accounting for 22%, 20% and 17% of total veterinary medicines sales, respectively.
Veterinary medicines III quarter 2026 in summary:
Veterinary medicinal products market: 5.1 mil euros
Sales to veterinarians: 4.7 mil euros
Sales to general and veterinary pharmacies: 0.4 mil euros
Antiparasitic products (QP): 1.1 mil euros
Immunologicals (QI): 1.0 mil euros
Antiinfectives for systemic use (QJ): 0.9 mil euros